NCT05261750

Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Safety and Efficacy of Adjuvant Therapy of Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: PT. Prodia Stem Cell Indonesia · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.

Detailed description

There are three arms controlled group. First group receives standard medical theraphy (radiotherapy or chemoradiation), second group who receives autologous dendritic cell (Auto-DC), and third group receives the combination of allogenic-dendritic cell-secretomes (Allo-DC Secretome) and continued with autologous dendritic cell (Auto-DC).

Conditions

• Nasopharyngeal Cancer

Interventions

Type	Name	Description
OTHER	Placebo (Aqua Pro-Injection)	Treatment with Aqua Pro-Injection 2 cc 2 times injection, interval 2 days (via Intramuscular).
BIOLOGICAL	Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy)	Treatment with Aqua Pro-Injection 2 cc, and then followed by Auto DC, interval 2 days (via Intramuscular)
BIOLOGICAL	Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy)	Treatment with Allo-DC-Secretome 2 cc, and then followed by Auto DC, interval 2 days (via Intramuscular)

Timeline

• Start date: 2022-04-30
• Primary completion: 2026-02-28
• Completion: 2026-02-28
• First posted: 2022-03-02
• Last updated: 2026-02-25

Locations

1 site across 1 country: Indonesia